Logo image of APUS

APIMEDS PHARMACEUTICALS US I (APUS) Stock Price, Quote, News and Overview

NYSEARCA:APUS - NYSE Arca - US03771D1028 - Common Stock - Currency: USD

1.79  -0.01 (-0.56%)

APUS Quote, Performance and Key Statistics

APIMEDS PHARMACEUTICALS US I

NYSEARCA:APUS (7/17/2025, 8:04:04 PM)

1.79

-0.01 (-0.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap20.73M
Shares11.58M
Float2.09M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO05-09 2025-05-09


APUS short term performance overview.The bars show the price performance of APUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 -1 2 -2

APUS long term performance overview.The bars show the price performance of APUS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of APUS is 1.79 USD. In the past month the price decreased by -2.72%.

APIMEDS PHARMACEUTICALS US I / APUS Daily stock chart

APUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.64 338.09B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.06 135.34B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.97B
REGN REGENERON PHARMACEUTICALS 12.41 59.38B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.34B
ARGX ARGENX SE - ADR 99.6 34.97B
ONC BEONE MEDICINES LTD-ADR 7.43 31.42B
BNTX BIONTECH SE-ADR N/A 26.69B
SMMT SUMMIT THERAPEUTICS INC N/A 20.52B
INSM INSMED INC N/A 19.76B
NTRA NATERA INC N/A 19.58B

About APUS

Company Profile

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.

Company Info

APIMEDS PHARMACEUTICALS US I

25 Edinburg Circle

Matawan NEW JERSEY US

Employees: 2

APUS Company Website

Phone: 18082097887

APIMEDS PHARMACEUTICALS US I / APUS FAQ

What is the stock price of APIMEDS PHARMACEUTICALS US I today?

The current stock price of APUS is 1.79 USD. The price decreased by -0.56% in the last trading session.


What is the ticker symbol for APIMEDS PHARMACEUTICALS US I stock?

The exchange symbol of APIMEDS PHARMACEUTICALS US I is APUS and it is listed on the NYSE Arca exchange.


On which exchange is APUS stock listed?

APUS stock is listed on the NYSE Arca exchange.


What is APIMEDS PHARMACEUTICALS US I worth?

APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 20.73M USD. This makes APUS a Nano Cap stock.


How many employees does APIMEDS PHARMACEUTICALS US I have?

APIMEDS PHARMACEUTICALS US I (APUS) currently has 2 employees.


What are the support and resistance levels for APIMEDS PHARMACEUTICALS US I (APUS) stock?

APIMEDS PHARMACEUTICALS US I (APUS) has a support level at 1.64 and a resistance level at 1.83. Check the full technical report for a detailed analysis of APUS support and resistance levels.


Should I buy APIMEDS PHARMACEUTICALS US I (APUS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APIMEDS PHARMACEUTICALS US I (APUS) stock pay dividends?

APUS does not pay a dividend.


What is the Short Interest ratio of APIMEDS PHARMACEUTICALS US I (APUS) stock?

The outstanding short interest for APIMEDS PHARMACEUTICALS US I (APUS) is 0.06% of its float. Check the ownership tab for more information on the APUS short interest.


APUS Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to APUS.


Chartmill TA Rating
Chartmill Setup Rating

APUS Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

APUS Ownership and Analysts


Ownership
Inst OwnersN/A
Ins Owners14.44%
Short Float %0.06%
Short Ratio0.05
Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A